IVBT (Innovation1 Biotech) ROC (Joel Greenblatt) %: -60,000.00% (As of Feb. 2024)


IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech ROC (Joel Greenblatt) %?

Innovation1 Biotech IVBT 12 ROC (Joel Greenblatt) % is -60,000.00% as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Innovation1 Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -60,000.00%.

The historical rank and industry rank for Innovation1 Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

IVBT's ROC (Joel Greenblatt) % is not ranked *
in the Diversified Financial Services industry.
Industry Median: -341.67
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Innovation1 Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Innovation1 Biotech  (OTCPK:IVBT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Innovation1 Biotech ROC (Joel Greenblatt) % Related Terms


Innovation1 Biotech ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech ROC (Joel Greenblatt) % Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -371.43 -2,819.78 84,000.00 -16,819.75 -2,355.65

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,039.08 -40,800.00 -867,800.00 -40,266.67 -60,000.00

IVBT vs NVIV, PXMD, SCNI: ROC (Joel Greenblatt) % Comparison

For the Shell Companies subindustry, Innovation1 Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation1 Biotech ROC (Joel Greenblatt) % vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's ROC (Joel Greenblatt) % falls into.


IVBT
12GF Score
Innovation1 Biotech Inc IVBT
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.606 + 0 + 4.4408920985006E-16)
=-2.595

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.854 + 0 + 0)
=-2.843

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Innovation1 Biotech for the quarter that ended in Feb. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.6/( ( (0.001 + max(-2.595, 0)) + (0.001 + max(-2.843, 0)) )/ 2 )
=-0.6/( ( 0.001 + 0.001 )/ 2 )
=-0.6/0.001
=-60,000.00 %

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -60,000.00% mean?
Innovation1 Biotech (IVBT) has a ROC (Joel Greenblatt) % of -60,000.00% as of Feb. 2024. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innovation1 Biotech and its competitors.
Is Innovation1 Biotech's ROC (Joel Greenblatt) % too high?
Innovation1 Biotech's current ROC (Joel Greenblatt) % is -60,000.00%. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's ROC (Joel Greenblatt) % compare to NVIV and PXMD?
Innovation1 Biotech's ROC (Joel Greenblatt) % of -60,000.00% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Diversified Financial Services company?
A good ROC (Joel Greenblatt) % depends on the Diversified Financial Services industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innovation1 Biotech and its competitors. Innovation1 Biotech's current ROC (Joel Greenblatt) % is -60,000.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current ROC (Joel Greenblatt) % of -60,000.00%. The current ROC (Joel Greenblatt) % is -60,000.00%. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current ROC (Joel Greenblatt) % is -60,000.00% as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price